Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12606000266561
Ethics application status
Not yet submitted
Date submitted
27/06/2006
Date registered
29/06/2006
Date last updated
29/06/2006
Type of registration
Prospectively registered
Titles & IDs
Public title
MACULAR THICKNESS CHANGES FOLLOWING THE USE OF PROSTAGLANDIN ANALOGUES IN PSEUDOPHAKIC PATIENTS
Query!
Scientific title
MACULAR THICKNESS CHANGES FOLLOWING THE USE OF PROSTAGLANDIN ANALOGUES IN PSEUDOPHAKIC PATIENTS
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Macular thickness will be evaluated accurately using optical coherence tomography (OCT) in pseudophakic patients using prostaglandin analogues
1243
0
Query!
Condition category
Condition code
Eye
1328
1328
0
0
Query!
Normal eye development and function
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Patients that underwent uncomplicated cataract surgery will be randomized to use topical bimatoprost 0.03% eye-drop q.d. (n=10), topical latanoprost 0.005% eye-drop q.d. (n=10), or topical travoprost 0.004% eye-drop q.d. (n=10) for 1 month.
Macular thickness will be evaluate using OCT at baseline, 15 days and 1 month.
The baseline will be used as control.
Query!
Intervention code [1]
1169
0
Treatment: Drugs
Query!
Comparator / control treatment
No control intervention.
Query!
Control group
Active
Query!
Outcomes
Primary outcome [1]
1814
0
Macular thickness changes after use of prostaglandin analogues in pseudophakic eyes.
Query!
Assessment method [1]
1814
0
Query!
Timepoint [1]
1814
0
At baseline, 15 days and 1 month.
Query!
Secondary outcome [1]
3180
0
None
Query!
Assessment method [1]
3180
0
Query!
Timepoint [1]
3180
0
Query!
Eligibility
Key inclusion criteria
Patients in the study will be subjects that underwent uneventful cataract surgery with intraocular lens implantation and that have follow-up visits at Ophthalmology Service – Federal University of Uberlândia.Patients were eligible for participation if they met the following inclusion criteria: pseudophakia, uneventful cataract surgery, and visual acuity better than 20/40.
Query!
Minimum age
40
Years
Query!
Query!
Maximum age
Not stated
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Patients were excluded from the study if they had a prior history of uveitis or CME, substantial ocular irritation at baseline, or history of intraocular surgery or laser procedure within 4 months before baseline. We also excluded patients who had been treated with PG analogues in the past, and patients who had undergone other ocular surgery except for cataract. Finally, the presence of systemic disorders that could be associated with either uveitis or CME (i.e. diabetes, rheumatologic diseases), pregnancy, lactation or inadequate contraception (in females) were also exclusion criteria.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Patients will be submitted to optical coherence tomography (OCT) evaluation at baseline and after 15 days and 1 month of treatment. A designated unmasked coordinator – who did not perform any study evaluation or assessment – will receive randomization codes, dispense the medications and instruct the patients on how to use and store the containers.
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
The web program Research Randomizer v3.0 (www.randomizer.org) will be use for random assignment.
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
none
Query!
Phase
Query!
Type of endpoint/s
Safety
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Not yet recruiting
Query!
Date of first participant enrolment
Anticipated
10/09/2006
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
30
Query!
Accrual to date
Query!
Final
Query!
Recruitment outside Australia
Country [1]
368
0
Brazil
Query!
State/province [1]
368
0
Query!
Funding & Sponsors
Funding source category [1]
1455
0
University
Query!
Name [1]
1455
0
Federal University of Uberlândia
Query!
Address [1]
1455
0
Query!
Country [1]
1455
0
Brazil
Query!
Primary sponsor type
University
Query!
Name
Federal University of Uberlândia
Query!
Address
Query!
Country
Brazil
Query!
Secondary sponsor category [1]
1284
0
None
Query!
Name [1]
1284
0
none
Query!
Address [1]
1284
0
Query!
Country [1]
1284
0
Query!
Ethics approval
Ethics application status
Not yet submitted
Query!
Ethics committee name [1]
2832
0
Ethics Committee of the Federal University of Uberlândia
Query!
Ethics committee address [1]
2832
0
Query!
Ethics committee country [1]
2832
0
Brazil
Query!
Date submitted for ethics approval [1]
2832
0
Query!
Approval date [1]
2832
0
Query!
Ethics approval number [1]
2832
0
Query!
Summary
Brief summary
The primary purpose of the protocol is to investigate the effects of prostaglandin analogues on the macular thickness in pseudophakic patients. Hypothesis: 1) The use of prostaglandin analogues in pseudophakic patients changes the macular thickness / 2) The use of prostaglandin analogues in pseudophakic patients does not change the macular thickness
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
35159
0
Query!
Address
35159
0
Query!
Country
35159
0
Query!
Phone
35159
0
Query!
Fax
35159
0
Query!
Email
35159
0
Query!
Contact person for public queries
Name
10358
0
Enyr Saran Arcieri
Query!
Address
10358
0
Rua Corcovado, n 155 - apto 402
Bairro Patrimônio
Uberlândia - Minas Gerais
CEP 38411-092
Query!
Country
10358
0
Brazil
Query!
Phone
10358
0
55-34-32559090
Query!
Fax
10358
0
55-34-32559090
Query!
Email
10358
0
[email protected]
Query!
Contact person for scientific queries
Name
1286
0
Enyr Saran Arcieri
Query!
Address
1286
0
Rua Corcovado, n 155 - apto 402
Bairro Patrimônio
Uberlândia - Minas Gerais - Brasil
CEP 38411-092
Query!
Country
1286
0
Brazil
Query!
Phone
1286
0
55-34-32559090
Query!
Fax
1286
0
55-34-32559090
Query!
Email
1286
0
[email protected]
Query!
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF